Session 4 : Triple Negative Breast Cancer

Triple Negative Breast Cancer by Chetan Deshmukh

Chairpersons :

K. Pavithran, N. K. Warrier

Speaker :

Chetan Deshmukh

ABC Joint Analysis: Optimal Chemotherapy Backbone for HER2-Negative EBC: TC vs TaxAC in HER2-Negative EBC (ABC Joint Analysis): Timeline, Accrual, Treatment

Author: Joanne Lorraine Blum

Conference: 2016 ASCO Annual Meeting, Abstract 1000

Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer, A Randomized Clinical Trial

Author: Theodoros Foukakis

Reference: JAMA. 2016;316(18):1888-1896

Comparison of four cycles epirubicin and cyclophosphamide (EC) followed by four cycles docetaxel (T) versus six cycles docetaxel and carboplatin (TP) as adjuvant chemotherapy for women with operable triple negative breast cancer

Author: Peng Yuan

Conference: 2016 ASCO Annual Meeting, Abstract 1068